Merck Sharp & Dohme
Merck Sharp & Dohme appears in FDA public data with 5 recalls — including 1 Class I (most serious) —, 0 510(k) clearances, 59 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0241-2026, Class II) was initiated on Dec 12, 2025.
Summary
- Total Recalls
- 5 (1 Class I)
- 510(k) Clearances
- 0
- Inspections
- 59
- Compliance Actions
- 0
Known Names
Merck Sharp And Dohme, Merck, Sharp And Dohme
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0241-2026 | Class II | Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Me | Dec 12, 2025 |
| D-0242-2026 | Class II | Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, | Dec 12, 2025 |
| D-0746-2022 | Class II | Janumet (sitagliptin and metformin HCl) tablets, 50 mg/500 mg, 14-count bottle, packaged as 2 bottle | Mar 31, 2022 |
| D-0093-2022 | Class I | Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sh | Oct 19, 2021 |
| D-0176-2021 | Class II | Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose vial, Rx only, Manuf. | Dec 21, 2020 |